Growth Metrics

Vera Therapeutics (VERA) Debt to Equity (2021 - 2023)

Vera Therapeutics posted quarterly Debt to Equity of $0.02 for Q1 2023, down 60.59% year-on-year from $0.05 in Q1 2022, and down 46.15% on a QoQ basis from $0.04 in Q4 2022.

Vera Therapeutics (VERA) has 3 years of Debt to Equity data on file, last reported at $0.02 in Q1 2023.

  • For the quarter ending Q1 2023, Debt to Equity fell 60.59% year-over-year to $0.02; the trailing twelve-month figure through Mar 2023 stood at $0.02 (down 60.59% YoY), and the FY2022 full-year result was $0.04, down 58.23% from the prior year.
  • Debt to Equity for Q1 2023 stood at $0.02, down from $0.04 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.09 in Q4 2021 and bottomed at $0.01 in Q3 2021.
  • The 3-year median for Debt to Equity is $0.05 (2022), against an average of $0.05.
  • The widest annual swing landed in 2022, when Debt to Equity jumped 388.38%; it then sank 60.59% in 2023.
  • A 3-year view of Debt to Equity shows it stood at $0.09 in 2021, then sank by 58.23% to $0.04 in 2022, then tumbled by 46.15% to $0.02 in 2023.
  • The last three Debt to Equity figures came in at $0.02 (Q1 2023), $0.04 (Q4 2022), and $0.06 (Q3 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.06
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Vera Therapeutics 2.43 Bn 1.83 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2023 0.02
Dec 31, 2022 0.04
Sep 30, 2022 0.06
Jun 30, 2022 0.06
Mar 31, 2022 0.05
Dec 31, 2021 0.09
Sep 30, 2021 0.01